MMP2 and MMP9 as candidate biomarkers to monitor bevacizumab therapy in high-grade glioma

Neuro-Oncology

Volumn 17, Issue 8, 2015, Pages 1174-1176

  Tabouret, Emeline ^a,b   Boudouresque, Francoise ^b   Farina, Patrizia ^a   Barrie, Maryline ^a   Bequet, Celine ^a   Sanson, Marc ^c,d   Chinot, Olivier ^a,b  

^a TIMONE HOSPITAL   (France)

^b University of the Mediterranean Aix Marseille II   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; GELATINASE A; GELATINASE B; IRINOTECAN; ANGIOGENESIS INHIBITOR; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CLINICAL ARTICLE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; TUMOR GROWTH; BLOOD; BRAIN NEOPLASMS; DISEASE COURSE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84943241606     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov094     Document Type: Letter

References (10)

1. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359(6398):845-848.
2. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
3. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
4. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
5. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
6. Tabouret E, Boudouresque F, Barrie M, et al. Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma. Neuro Oncol. 2014;16(3):392-399.
7. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817-2823.
8. Chetty C, Lakka SS, Bhoopathi P, et al. MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKTsignaling in A549 lung cancer cells. Int J Cancer. 2010;127(5):1081-1095.
9. Du R, Petritsch C, Lu K, et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008;10(3):254-264.
10. Ahn G-O, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008;13(3):193-205.